Evaluation of the Effectiveness of The Volara System Determined by Sputum Movement and Production

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-05-31

Study Completion Date

2025-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to evaluate the therapeutic effect of therapy with The Volara System on mucus clearance.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Use of Endobronchial Valves in Non-Upper Lobe Heterogeneous Emphysema

NCT00825578

Heterogeneous Emphysema

COMPLETED PHASE3

Collateral Ventilation Effects on Response to AeriSeal System Treatment in Upper Lobe Predominant Emphysema

NCT01520740

Pulmonary Emphysema

TERMINATED PHASE4

To Improve Lung Function and Symptoms for Emphysema Patients Using Zephyr Valves

NCT02022683

COPD Heterogeneous Emphysema

COMPLETED NA

Assessing the Utility of Peak Inspiratory Flow as a Predictor for COPD Exacerbations

NCT04360226

Chronic Obstructive Pulmonary Disease

COMPLETED

A Trial on the Effects of Bronchoscopic Lung Volume Reduction in Severe Emphysema.

NCT03474471

Emphysema

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The aim of this study is to evaluate the therapeutic effect of therapy with The Volara System on mucus clearance. Mucus volume (mL) measured by Functional Respiratory Imaging (FRI). FRI is a quantitative endpoint that identifies mucus plugs in the segmented airways. Mucus volume will be assessed based on movement of mucus plugs and/or clearance from segmental airways. CT scans are obtained to determine FRI and will be obtained and assessed at baseline and after the 4-week treatment period to assess changes in mucus volume within the airways, associated with the Volara treatment. The study will also provide insight into the mechanism of action of the therapy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bronchiectasis Adult COPD

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

This study will be a single arm, monocentric, prospective, pilot study.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Single Group Assignment

Each participant will be his/her own control comparing their baseline status to an active treatment period.

Group Type EXPERIMENTAL

Volara therapy

Intervention Type DEVICE

Oscillation and Lung Expansion (OLE) therapy, is a respiratory airway clearance intervention including continuous high-frequency oscillation and continuous positive expiratory pressure

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Volara therapy

Oscillation and Lung Expansion (OLE) therapy, is a respiratory airway clearance intervention including continuous high-frequency oscillation and continuous positive expiratory pressure

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Documented diagnosis of COPD with or without bronchiectasis.
2. Age ≥ 21 years.
3. Naive to Volara therapy.
4. FEV1 \< 80% predicted (based on pulmonary function tests within the past 12 months).
5. Daily sputum production over the prior 2 weeks.
6. Signed informed consent.
7. Stable pulmonary disease defined as no change in disease status.
8. Stable medication regimen for 30 days prior to visit 1, defined as no change in prescribed medications and adherence to their prescribed medications for pulmonary disease

Exclusion Criteria

1. Anticipated requirement for hospitalisation within the next 35 days (± 1 day).
2. History of pneumothorax within the past 6 months prior to visit 1.
3. History of haemoptysis requiring embolization within the past 12 months prior to visit 1.
4. Inability or unwillingness to perform Volara System therapy as directed, without healthcare provider support.
5. Inability or unwillingness to complete study visits and/or provide follow-up data as required per the study protocol.
6. Inability to complete a 6-minute walk.
7. Actively participating in another clinical trial involving an investigational medication or device.
8. Pregnant females as verified by point of care human chorionic gonadotropin test.
9. Current Intrapulmonary Percussive Ventilation and/or oscillation and lung expansion users.
10. Participant requires a prescribed daily regimen for airway clearance with a device or with manual therapy in addition to Volara.
11. Participant requires mechanical ventilation.
12. Participants with artificial airways

Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No